29 related articles for article (PubMed ID: 19615842)
1. Isolation and Structure Determination of Echinochrome A Oxidative Degradation Products.
Mishchenko NP; Vasileva EA; Gerasimenko AV; Grigorchuk VP; Dmitrenok PS; Fedoreyev SA
Molecules; 2020 Oct; 25(20):. PubMed ID: 33080948
[TBL] [Abstract][Full Text] [Related]
2. Response of lipid metabolism, energy supply, and cell fate in yellowstripe goby (Mugilogobius chulae) exposed to environmentally relevant concentrations atorvastatin.
Zhao Y; Duan C; Zhang H; Gong W; Wang Y; Ren J; Nie X; Li J
Environ Pollut; 2024 Jan; 341():122991. PubMed ID: 37995957
[TBL] [Abstract][Full Text] [Related]
3. Using Nuclear Magnetic Resonance to Troubleshoot a Stability Issue in a Real-World Formulation Chassis-Application to Consumer Oral Healthcare.
Coban T; Sykes H; Kulkarni S; Lucas RA; Robertson C; Le Gresley A
Pharmaceutics; 2024 Feb; 16(3):. PubMed ID: 38543214
[TBL] [Abstract][Full Text] [Related]
4. Stress Degradation Behavior of Atorvastatin Calcium and Development of a Suitable Stability-Indicating LC Method for the Determination of Atorvastatin, its Related Impurities, and its Degradation Products.
Vukkum P; Moses Babu J; Muralikrishna R
Sci Pharm; 2013; 81(1):93-114. PubMed ID: 23641331
[TBL] [Abstract][Full Text] [Related]
5. Oxidation of Drugs during Drug Product Development: Problems and Solutions.
Gabrič A; Hodnik Ž; Pajk S
Pharmaceutics; 2022 Jan; 14(2):. PubMed ID: 35214057
[TBL] [Abstract][Full Text] [Related]
6. Spectroscopic studies on photodegradation of atorvastatin calcium.
Oprica M; Iota M; Daescu M; Fejer SN; Negrila C; Baibarac M
Sci Rep; 2021 Jul; 11(1):15338. PubMed ID: 34321518
[TBL] [Abstract][Full Text] [Related]
7. Analytical Quality by Design Approach of Reverse-Phase High-Performance Liquid Chromatography of Atorvastatin: Method Development, Optimization, Validation, and the Stability-Indicated Method.
Alruwaili NK
Int J Anal Chem; 2021; 2021():8833900. PubMed ID: 33628253
[TBL] [Abstract][Full Text] [Related]
8. Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation.
Khan FN; Dehghan MH
AAPS PharmSciTech; 2011 Dec; 12(4):1077-86. PubMed ID: 21879394
[TBL] [Abstract][Full Text] [Related]
9. The use of liquid chromatography-mass spectrometry for the identification of drug degradation products in pharmaceutical formulations.
Wu Y
Biomed Chromatogr; 2000 Oct; 14(6):384-96. PubMed ID: 11002276
[TBL] [Abstract][Full Text] [Related]
10. Isolation and structure determination of oxidative degradation products of atorvastatin.
Kracun M; Kocijan A; Bastarda A; Grahek R; Plavec J; Kocjan D
J Pharm Biomed Anal; 2009 Dec; 50(5):729-36. PubMed ID: 19615842
[TBL] [Abstract][Full Text] [Related]
11. Validation of HPLC method for determination of atorvastatin in tablets and for monitoring stability in solid phase.
Stanisz B; Kania L
Acta Pol Pharm; 2006; 63(6):471-6. PubMed ID: 17438862
[TBL] [Abstract][Full Text] [Related]
12. Stability indicating UPLC method for simultaneous determination of atorvastatin, fenofibrate and their degradation products in tablets.
Kadav AA; Vora DN
J Pharm Biomed Anal; 2008 Sep; 48(1):120-6. PubMed ID: 18583084
[TBL] [Abstract][Full Text] [Related]
13. A prediction system of oxidation reaction as a solid-state stress condition: applied to a pyrrole-containing pharmaceutical compound.
Kawaguchi-Murakami Y; Fukutsu N; Kajiro T; Araki T; Murakami T; Kawasaki T; Kishi N; Konno M
J Pharm Biomed Anal; 2009 Oct; 50(3):328-35. PubMed ID: 19497698
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
